Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial report
Rattachement africain : us, sg, gb, au, ca. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
IMPORTANCE: Greater levels of treatment resistance in major depressive disorder (MDD) are associated with lower rates of initial benefit and higher rates of relapse (lower durability). OBJECTIVE: Characterize depressive symptoms, function, and quality of life (QoL) over 24 months of adjunctive vagus nerve stimulation (VNS) in participants with markedly treatment-resistant depression. DESIGN: Prospective, open-label, single-arm, long-term extension study (RECOVER) conducted from September 2019 to April 2025. SETTING: Outpatient. PARTICIPANTS: Adults with moderate-severe MDD with ≥ 4 failed antidepressant trials in the current episode, randomized to blinded, adjunctive VNS for 12 months, who subsequently received open-label, adjunctive VNS for 12 additional months (n = 214). INTERVENTIONS: Vagus nerve stimulation and concomitant psychotropic medications and interventional psychiatric modalities (electroconvulsive therapy, transcranial magnetic stimulation, and ketamine/esketamine) were characterized over the 12-month extension. MAIN OUTCOMES AND MEASURES: The durability of benefit achieved at 12 months was assessed at 18 and 24 months for depressive symptoms (3 scales), daily function, QoL, a tripartite composite of all 3 domains, and the Clinical Global Impression-Improvement (CGI-I) scale (overall improvement). Loss of benefit and relapse were assessed, along with the emergence of meaningful benefit in participants without benefit at 12 months. Substantial benefit (at least 50% symptom reduction from baseline; CGI-I of 1 or 2; tripartite measures with at least 2 of 3 subscales evidencing benefit) and meaningful benefit thresholds for symptoms (at least 30% reduction from baseline), function, QoL, CGI-I, and the tripartite measure were set a priori. RESULTS: Most participants with substantial benefit maintained their benefit (18-month median = 78.8%; 24-month median = 79.0% across 5 measures), as did participants with at least meaningful benefit at 12 months (18-month median = 83.1%; 24-month median = 81.3% across 7 measures). Furthermore, many participants with no meaningful benefit at 12 months achieved it at 18 (median = 30.6%) and 24 (median = 37.8%) months. The strong maintenance of benefit was not accounted for by changes in psychotropic medications or interventional psychiatric modalities. CONCLUSIONS AND RELEVANCE: Depressive symptom, daily function, and QoL benefits obtained after 12 months of adjunctive VNS were sustained in about 80% of participants continuing VNS. Approximately 30% with no meaningful benefit at 12 months accrued increased benefit over the subsequent year.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial report
- Date Crossref
- 01/01/2026
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Washington University in St. Louis pays non établi dans la noticeUniversité ou école supérieure
-
Duke-NUS Medical School pays non établi dans la noticeUniversité ou école supérieure
-
Sheppard Pratt Health System pays non établi dans la noticeÉtablissement de santé
-
LivaNova (United Kingdom) pays non établi dans la noticeEntreprise
-
Medical University of South Carolina Department of Psychiatry pays non établi dans la noticeUniversité ou école supérieure
-
Ralph H. Johnson VA Medical Center pays non établi dans la noticeÉtablissement de santé
-
Emory University Department of Psychiatry and Behavioral Sciences pays non établi dans la noticeUniversité ou école supérieure
-
Perinatal Treatment Services pays non établi dans la noticeÉtablissement de santé
-
University of Minnesota Department of Psychiatry and Behavioral Sciences pays non établi dans la noticeUniversité ou école supérieure
-
Rush University Medical Center Department of Psychiatry and Behavioral Sciences pays non établi dans la noticeÉtablissement de santé
-
Psychiatric Medicine Associates pays non établi dans la noticeÉtablissement de santé
-
Center for Anxiety and Depression pays non établi dans la noticeÉtablissement de santé
Washington University in St. Louis, Duke-NUS Medical School et Sheppard Pratt Health System, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.